Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.260
-0.030 (-2.33%)
May 14, 2026, 2:03 PM EDT - Market open
Actinium Pharmaceuticals Revenue
Actinium Pharmaceuticals had revenue of $90.00K in the twelve months ending March 31, 2026. In the year 2025, Actinium Pharmaceuticals had annual revenue of $90.00K.
Revenue (ttm)
$90.00K
Revenue Growth
n/a
P/S Ratio
446.86
Revenue / Employee
$3,600
Employees
25
Market Cap
39.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 81.00K | -949.00K | -92.14% |
| Dec 31, 2022 | 1.03M | -114.00K | -9.97% |
| Dec 31, 2021 | 1.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Plus Therapeutics | 5.21M |
| Aligos Therapeutics | 4.71M |
| Nutriband | 2.04M |
| RenovoRx | 1.12M |
| Daré Bioscience | 1.03M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| INmune Bio | 50.00K |
ATNM News
- 8 days ago - Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - PRNewsWire
- 22 days ago - Actinium presents data from Actimab-A studies at AACR - TheFly
- 22 days ago - Actinium presents preclinical results for ATNM-400 at AACR - TheFly
- 22 days ago - Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting - PRNewsWire
- 22 days ago - Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PRNewsWire
- 4 weeks ago - NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225 - Business Wire
- 5 weeks ago - Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - PRNewsWire
- 3 months ago - BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research - Business Wire